Literature DB >> 15931266

Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation.

S Barrena1, J Almeida, M Yunta, A López, N Fernández-Mosteirín, M Giralt, M Romero, L Perdiguer, M Delgado, A Orfao, P A Lazo.   

Abstract

Tetraspanin proteins form signaling complexes between them and with other membrane proteins and modulate cell adhesion and migration properties. The surface expression of several tetraspanin antigens (CD9, CD37, CD53, CD63, and CD81), and their interacting proteins (CD19, CD21, and HLA-DR) were analyzed during normal B-cell maturation and compared to a group of 67 B-cell neoplasias. Three patterns of tetraspanin expression were identified in normal B cells. The first corresponded to bone marrow CD10(+) B-cell precursors (BCP) which showed high expression of CD81 and CD9, low reactivity for CD53 and negativity for CD37. CD10(-) B-lymphocytes showed downregulation of CD9/CD81 and upregulation of CD53/CD37. Plasma cells showed re-expressed CD9 and downregulated CD37. Hierarchical clustering analysis of flow cytometry immunophenotypic data showed a good correlation between the tumor differentiation stage and the pattern of tetraspanin expression, with all analyzed individual samples classified into three major groups, independently of their normal or neoplastic origin. Despite this, neoplastic B-cells frequently showed aberrantly high/low expression of the different markers analyzed. Interestingly, in B-cell chronic lymphocytic leukemia, abnormal expression of CD53 and CD9 were associated with different patterns of disease infiltration, which would support the role of these molecules on modulating adhesion and migration of neoplastic B cells. Leukemia (2005) 19, 1376-1383.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931266     DOI: 10.1038/sj.leu.2403822

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Authors:  Daniel S Pereira; Claudia I Guevara; Liqing Jin; Nathan Mbong; Alla Verlinsky; Ssucheng J Hsu; Hector Aviña; Sher Karki; Joseph D Abad; Peng Yang; Sung-Ju Moon; Faisal Malik; Michael Y Choi; Zili An; Kendall Morrison; Pia M Challita-Eid; Fernando Doñate; Ingrid B J Joseph; Thomas J Kipps; John E Dick; David R Stover
Journal:  Mol Cancer Ther       Date:  2015-05-01       Impact factor: 6.261

3.  High frequency of inactivating tetraspanin C D37 mutations in diffuse large B-cell lymphoma at immune-privileged sites.

Authors:  Suraya Elfrink; Charlotte M de Winde; Michiel van den Brand; Madeleine Berendsen; Margaretha G M Roemer; Frank Arnold; Luuk Janssen; Alie van der Schaaf; Erik Jansen; Patricia J T A Groenen; Astrid Eijkelenboom; Wendy Stevens; Corine J Hess; J Han van Krieken; Joost S P Vermaat; Arjen H G Cleven; Ruben A L de Groen; Viviana Neviani; Daphne de Jong; Sjoerd van Deventer; Blanca Scheijen; Annemiek B van Spriel
Journal:  Blood       Date:  2019-07-31       Impact factor: 22.113

Review 4.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

5.  SMIP-016 in action: CD37 as a death receptor.

Authors:  Lei Jin; John C Cambier
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

6.  Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Authors:  Ajay K Gopal; Stefano R Tarantolo; Naresh Bellam; Damian J Green; Melissa Griffin; Tatyana Feldman; Anthony R Mato; Amy J Eisenfeld; Scott C Stromatt; Andre Goy
Journal:  Invest New Drugs       Date:  2014-06-15       Impact factor: 3.850

7.  Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Authors:  Hakan Köksal; Pierre Dillard; Sarah E Josefsson; Solrun Melkorka Maggadottir; Sylvie Pollmann; Anne Fåne; Yngvild Nuvin Blaker; Klaus Beiske; Kanutte Huse; Arne Kolstad; Harald Holte; Gunnar Kvalheim; Erlend B Smeland; June H Myklebust; Else Marit Inderberg; Sébastien Wälchli
Journal:  Blood Adv       Date:  2019-04-23

8.  Open conformation of tetraspanins shapes interaction partner networks on cell membranes.

Authors:  Yihu Yang; Xiaoran Roger Liu; Zev J Greenberg; Fengbo Zhou; Peng He; Lingling Fan; Shixuan Liu; Guomin Shen; Takeshi Egawa; Michael L Gross; Laura G Schuettpelz; Weikai Li
Journal:  EMBO J       Date:  2020-08-16       Impact factor: 11.598

9.  Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.

Authors:  Dominik F Draxler; Lisa M Wutzlhofer; Georg Slavka; Wolfgang Hübl; Heinz Ludwig; Martin Schreder; John Reynolds; Martin Willheim
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-07       Impact factor: 0.900

Review 10.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.